Javelin Pharmaceuticals, Inc. has signed a commercial supply agreement with Precision Pharma Services. Under the agreement, Precision will manufacture vials of Javelin’s injectable Dyloject product for use in European markets, pending regulatory approval. The agreement has a two-year, renewable term and includes minimum purchase and production requirements.

“This agreement is an important step forward in growing Javelin’s manufacturing infrastructure in anticipation of initial product sales later this year in Europe,” said Michael Moshman, Javelin’s vice president for clinical and commercial manufacturing. “Working with Precision Pharma will enable us to marshal the resources to meet future demand for Dyloject as we begin commercializing this promising analgesic with its launch in the UK in 2007.”